Skip to main content
Omvoh (mirikizumab-mrkz) logo
  • Prescribing Information
  • Medication Guide
  • Instructions for Use
Menu closed
Omvoh (mirikizumab-mrkz) logo
  • Prescribing Information
  • Medication Guide
  • Instructions for Use
Globe Loading... Reveal available languages
  • House For Consumers
    • What Is Omvoh?
      • Omvoh for Ulcerative Colitis
      • About Ulcerative Colitis
      • Omvoh Results
      • Omvoh for Crohn’s Disease
      • About Crohn’s Disease
      • Omvoh Results
      • Taking Omvoh
      • Start with IV Infusions
      • Continue with Injections
      • Savings and Support
      • Lilly Together™
      • Pricing Information
    • Living With IBD
  • For Healthcare Providers
Ask Lilly

We're here to help.

Phone Call:
1-800-LillyRx
(1-800-545-5979)
Expand contact lilly
man outdoors staring out into the distanceman outdoors staring out into the distance

Onward with Omvoh

Omvoh helps improve bowel urgency*

For adults with moderate to severe ulcerative colitis

Rapid

Relief

Rapid Relief

Rapid symptom relief is possible at Week 3†

Lasting

Remission

Lasting Remission

At 12 weeks, ~1 in 4 people achieved remission

66% of them maintained remission at one year

Improved

Bowel Urgency

Improved Bowel Urgency

No to minimal bowel urgency in some people taking Omvoh*

At 12 weeks, 24% of people achieved clinical remission and 65% reported improved UC symptoms.

Among the people who had improvement at 12 weeks, 51% achieved clinical remission at 1 year.

*Some patients saw improvement at Week 12, defined as a weekly average urgency score of 0 to 1. Urgency was rated from 0 (no urgency) to 10 (worst possible urgency).

†Less rectal bleeding and fewer bowel movements.

SELECT SAFETY INFORMATION
Omvoh may cause liver problems. Your healthcare provider will do blood tests to check your liver enzymes and bilirubin levels before, during, and after treatment with Omvoh. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including: unexplained rash, nausea, vomiting, stomach-area (abdominal) pain, feeling tired, loss of appetite, yellowing of the skin or the whites of your eyes, or dark urine.

Man sitting in a library. He is smiling and looking into the distance while holding a red book
 Lilly Support Services logo

Savings & Support with Lilly Support Services™ for Omvoh

Lilly Support Services can help you throughout your Omvoh treatment journey.

Learn More

Discussing Your Symptoms

Discussing the impact of your UC symptoms, like bowel urgency, with your doctor is an important first step.

Discussing the impact of your UC symptoms, like bowel urgency, with your doctor is an important first step.

Get Started
doctor speaking to her patient

Glenn's UC is in remission, thanks to Omvoh. Hear his story.

00:00 [Glenn seated in a white room, talking to the camera with Omvoh® (mirikizumab-mrkz) logo]
GLENN: I want to help more people like me get the answers they want.

00:02 [Blue screen, Omvoh¨ (mirikizumab-mrkz) logo appears, chat icon, and upbeat screen music]
CAPTION: Omvoh¨ (mirikizumab-mrkz) PRESENTS ASK ME ANYTHING, Stay tuned for Omvoh Safety Summary at the end of this video.

00:06 [Omvoh¨ (mirikizumab-mrkz) logo and ongoing upbeat background music]
CAPTION: Glenn, Remission. Stay tuned for Omvoh Safety Summary at the end of this video.

Indication: Omvoh is a prescription medicine that is used to treat adults with moderate to severe ulcerative colitis (UC). Select Safety Information: Omvoh may cause serious allergic reactions that may need to be treated in a hospital and may be life-threatening. Stop using Omvoh and get emergency medical help right away if you develop symptoms of a serious allergic reaction such as: fainting, dizziness, feeling lightheaded, swelling of your face, throat, or trouble swallowing, trouble breathing, throat tightening or wheezing, chest tightness, fast heartbeat, severe itching, hives, or redness all over your body, or sweating.

00:11 [Glenn talking to the camera, Glenn - Real Omvoh Patient banner]
GLENN: Hi I'm Glenn. My ulcerative colitis is in remission thanks to treatment with Omvoh. Ask me anything about my UC and I'll share my story.

CAPTION:Glenn - Real Omvoh Patient. Glenn is a real patient, sharing personal experiences, which may not apply to all Omvoh patients. Consult your healthcare provider to learn more or to see if Omvoh is right for you. Glenn was compensated for his time.
Among people who saw improvement at12 weeks, 51% Reached remission at 1 year.

00:21 [Blue screen, Omvoh¨ (mirikizumab-mrkz) logo, Glenn narrating words on screen.]
GLENN: The decision to change to a new medication isn't always easy. How did you adapt to this uncertainty?
CAPTION: The decision to change to a new medication isn't always easy. How did you adapt to this uncertainty?

00:27 [Glenn talking to the camera, Glenn - Real Omvoh Patient banner]
GLENN: So starting something new, especially for your own health, it was a little difficult for me to make the decision. I spoke to my doctor. For me, the choice was Omvoh. And of course I was a little worried. Was I going to get results? Was the situation going to get worse? But I was willing to go through that. I, I needed it, and I needed my symptoms to, to abate. My advice to anyone out there with moderate to severe UC is talk to your doctor. If Omvoh's right for you, give it a try.

00:59 [Blue screen, Omvoh® (mirikizumab-mrkz) logo, Glenn narrating words on screen.]
GLENN: What is it like to have your UC in remission?
CAPTION: What is it like to have your UC in remission?

01:02 [Glenn talking to the camera]
GLENN: Having my UC in remission is, is a marvelous thing. I'm enjoying life's little pleasures again. Without bowel urgency being the first thing on my mind. I can go to a movie and enjoy myself. I can get through an entire workout without, without issues at the gym. I can simply be myself with my friends now. It's a great thing.
CAPTION: At 12 weeks, ~1 in 4 people taking Omvoh reached remission, and 66% of them maintained remission at 1 year.

01:22 [Glenn talking to the camera]
GLENN: My ulcerative colitis is in remission thanks to treatment with Omvoh.
CAPTION: At 12 weeks, ~1 in 4 people taking Omvoh reached remission, and 66% of them maintained remission at 1 year.

01:26 [Glenn talking to the camera]
GLENN: I'm glad I could share my UC journey with you.

01:28 [Blue screen, Omvoh® (mirikizumab-mrkz) logo, Glenn narrating the caption building on the screen.]
GLENN: Thanks for joining.
CAPTION: See Indications and Safety summary in this video. Find more of Glenn's Ask Me Anything journey at youtube.com/@OmvohUS

01:30 [Glenn signing off, smiling and waving to the camera]
CAPTION: See Indications and Safety Summary in this video.

01:35 [Blue screen, large Omvoh® (mirikizumab-mrkz) logo animating on and off the screen to the bottom right.]
CAPTION: See Indications and Safety Summary in this video

01:37 [Blue screen with Omvoh® (mirikizumab-mrkz) logo in the bottom right corner, indications statement and safety summary scrolling on screen while spoken by AI.]
AI VO and CAPTION:

INDICATIONS AND SAFETY SUMMARY

Omvoh® (ahm-VOH) is a medicine used to treat

  • adults with moderately to severely active ulcerative colitis
  • adults with moderately to severely active Crohn’s disease

It is not known if Omvoh is safe and effective in children under 18 years of age.

Warnings – Omvoh can cause serious side effects including:

Serious allergic reactions: Omvoh may cause serious allergic reactions that may need to be treated in a hospital and may be life-threatening. Do not use Omvoh if you have had a serious allergic reaction to mirikizumab-mrkz or any of the ingredients in Omvoh. See the Medication Guide that comes with Omvoh for a list of ingredients. Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:

  • fainting, dizziness, feeling lightheaded
  • swelling of your face, eyelids, lips, mouth, tongue, throat, or trouble swallowing
  • trouble breathing, throat tightening, or wheezing
  • chest tightness
  • fast heartbeat or pounding in your chest
  • severe itching, hives, or redness all over your body
  • sweating

Infections: Omvoh may lower the ability of your immune system to fight infections and may increase your risk of infections. If you have an infection, your healthcare provider should not start treatment with Omvoh until your infection is gone. Before starting treatment with Omvoh, your healthcare provider should assess you for tuberculosis (TB). If you are at risk for TB, you may be treated with medicine for TB before you begin treatment with Omvoh. Your healthcare provider should watch you closely for signs and symptoms of TB while you are being treated with Omvoh and after treatment.
Before starting Omvoh, tell your healthcare provider if you think you have an infection or have symptoms of an infection, such as:

  • fever, sweating, or chills
  • muscle aches and pain
  • cough or shortness of breath
  • blood in your mucus (phlegm)
  • flu-like symptoms
  • headache
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • weight loss
  • nausea or vomiting
  • pain during urination

After starting Omvoh, tell your healthcare provider right away if you have any symptoms of an infection.

Liver Problems: Omvoh may cause liver problems. Your healthcare provider should do blood tests to check your liver enzyme and bilirubin levels before treatment, during, and after treatment with Omvoh. Your healthcare provider may hold or stop treatment if needed. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including

  • unexplained rash
  • nausea
  • vomiting
  • stomach-area (abdominal) pain
  • feeling tired
  • loss of appetite
  • yellowing of the skin or the whites of your eyes
  • dark urine

Common side effects

The most common side effects of Omvoh in people treated for ulcerative colitis include:

  • upper respiratory infections
  • injection site reaction
  • joint pain
  • rash
  • headache
  • herpes viral infections

The most common side effects of Omvoh in people treated for Crohn’s disease include:

  • upper respiratory infections
  • injection site reactions
  • headache
  • joint pain
  • elevated liver blood tests

These are not all the possible side effects of Omvoh.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before you use Omvoh, review these questions with your doctor:

  • Are you being treated for an infection?
  • Do you have an infection that does not go away or keeps coming back?
  • Do you have TB or have you been in close contact with someone with TB?
  • Do you have any possible symptoms of an infection such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, or pain during urination?

Tell your doctor about all your medical conditions, including if:

  • You have a history of serious allergic reaction to Omvoh, any infections or liver problems.
  • You need any vaccines or have had one recently. Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during or right after treatment with Omvoh. Tell your healthcare provider that you are taking Omvoh before receiving a vaccine.
  • You are pregnant, or plan to become pregnant. It is not known if Omvoh will harm your unborn baby. There will be a pregnancy registry to collect information about women who are exposed to Omvoh during pregnancy. If you become pregnant while taking Omvoh, you are encouraged to report your pregnancy to Eli Lilly and Company at 1-800-545-5979.
  • You are breastfeeding or plan to breastfeed. It is not known if Omvoh passes into your breastmilk.
  • You take prescription or over-the-counter medicines, vitamins, or herbal supplements.

How to take

Follow your healthcare provider’s instructions for using Omvoh. You will receive your first 3 doses of Omvoh through a vein in your arm (intravenous infusion) in a healthcare facility by a healthcare provider every 4 weeks. Each infusion will last about 30 minutes (for ulcerative colitis) or about 90 minutes (for Crohn’s disease). After induction, you will continue to receive Omvoh maintenance doses as self-injections under the skin (subcutaneous injection) every 4 weeks. For these injections, Omvoh is available as prefilled pens or prefilled syringes. For a full dose you will need two injections with either two prefilled pens or two prefilled syringes. Inject 1 Omvoh prefilled pen or prefilled syringe followed right away by the other Omvoh prefilled pen or prefilled syringe. If you give injections at home, you should be trained on the correct way to prepare and inject Omvoh. Do not try to inject Omvoh yourself until you or your caregiver have been shown how to inject. Read the detailed Instructions for Use about how to use and dispose of Omvoh the correct way.

Learn more

Omvoh is a prescription medicine. During induction, Omvoh is available as a single-dose vial for intravenous infusion containing 300 mg/15 mL that is administered in a healthcare facility.

During maintenance, Omvoh is available as:

  • For ulcerative colitis: two 100 mg/mL prefilled pens or prefilled syringes.
  • For Crohn’s disease: one 100 mg/mL prefilled pen or prefilled syringe and one 200 mg/2 mL prefilled pen or prefilled syringe.

For more information, call 1-800-545-5979 or go to omvoh.lilly.com.

This summary provides basic information about Omvoh but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Omvoh and how to take it. Your doctor is the best person to help you decide if Omvoh is right for you.

MR CON BS CD APP

Omvoh® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Voiceover audio created using AI

10:46 [Lilly A MEDICINE COMPANY logo bottom left]

10:48 [White screen with Omvoh® (mirikizumab-mrkz) A Lilly Medicine centered logo, music and voiceover stop]
CAPTION: Visit omvoh.lilly.com, Call 1-800-LillyRx Omvoh® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. PP-MR-US-0950 02/2025 ©Lilly USA, LLC 2025. All rights reserved.

10:22 [Animating Lilly A Medicine Company logo]

Your ulcerative colitis story can be an inspiration

Share your story with Omvoh . We might be back in touch to talk about sharing your experience in our materials to help motivate others.

Get Omvoh updates & support

Whether you want to learn more about Omvoh or are just getting started on treatment, we're here to support you.

phone screen preview of a message from Omvoh

Learn more about Omvoh for ulcerative colitis

Omvoh Results

Learn how to take Omvoh for ulcerative colitis

Get Started

Understand ulcerative colitis and learn about treatment goals

About UC

SAFETY SUMMARY

Warning:

Warnings – Omvoh can cause serious side effects including:
Serious allergic reactions: Omvoh may cause serious allergic reactions that may need to be treated in a hospital and may be life-threatening. Do not use Omvoh if you have had a serious allergic reaction to mirikizumab-mrkz or any of the ingredients in Omvoh. See the Medication Guide that comes with Omvoh for a list of ingredients. Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:

  • fainting, dizziness, feeling lightheaded
  • swelling of your face, eyelids, lips, mouth, tongue, throat, or trouble swallowing
  • trouble breathing, throat tightening, or wheezing
  • chest tightness
  • fast heartbeat or pounding in your chest
  • severe itching, hives, or redness all over your body
  • sweating

Infections: Omvoh may lower the ability of your immune system to fight infections and may increase your risk of infections. If you have an infection, your healthcare provider should not start treatment with Omvoh until your infection is gone.

Before starting treatment with Omvoh, your healthcare provider should assess you for tuberculosis (TB). If you are at risk for TB, you may be treated with medicine for TB before you begin treatment with Omvoh. Your healthcare provider should watch you closely for signs and symptoms of TB while you are being treated with Omvoh and after treatment.
Before starting Omvoh, tell your healthcare provider if you think you have an infection or have any symptoms of an infection, such as:

  • fever, sweating, or chills
  • muscle aches and pain
  • cough or shortness of breath
  • blood in your mucus (phlegm)
  • flu-like symptoms
  • headache
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • weight loss
  • nausea or vomiting
  • pain during urination

After starting Omvoh, tell your healthcare provider right away if you have any symptoms of an infection.

Liver Problems: Omvoh may cause liver problems. Your healthcare provider should do blood tests to check your liver enzyme and bilirubin levels before treatment, during, and after treatment with Omvoh. Your healthcare provider may hold or stop treatment if needed. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including:

  • unexplained rash
  • nausea
  • vomiting
  • stomach-area (abdominal) pain
  • feeling tired
  • loss of appetite
  • yellowing of the skin or the whites of your eyes
  • dark urine

Common side effects

The most common side effects of Omvoh in people treated for ulcerative colitis include:

  • upper respiratory infections
  • injection site reactions
  • joint pain
  • rash
  • headache
  • herpes viral infections

The most common side effects of Omvoh in people treated for Crohn’s disease include:

  • upper respiratory infections
  • injection site reactions
  • headache
  • joint pain
  • elevated liver blood tests

These are not all the possible side effects of Omvoh.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before you use Omvoh, review these questions with your doctor:

  • Are you being treated for an infection?
  • Do you have an infection that does not go away or keeps coming back?
  • Do you have TB or have you been in close contact with someone with TB?
  • Do you have any possible symptoms of an infection such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, or pain during urination?

Tell your doctor about all your medical conditions, including if:

  • You have a history of serious allergic reaction to Omvoh, any infections or liver problems.
  • You need any vaccines or have had one recently. Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during or right after treatment with Omvoh. Tell your healthcare provider that you are taking Omvoh before receiving a vaccine.
  • You are pregnant, or plan to become pregnant. It is not known if Omvoh will harm your unborn baby. There will be a pregnancy registry to collect information about women who are exposed to Omvoh during pregnancy. If you become pregnant while taking Omvoh, you are encouraged to report your pregnancy to Eli Lilly and Company at 1-800-545-5979.
  • You are breastfeeding or plan to breastfeed. It is not known if Omvoh passes into your breastmilk.
  • You take prescription or over-the-counter medicines, vitamins, or herbal supplements.

How to take

Follow your healthcare provider’s instructions for using Omvoh. You will receive your first 3 doses of Omvoh through a vein in your arm (intravenous infusion) in a healthcare facility by a healthcare provider every 4 weeks. Each infusion will last about 30 minutes (for ulcerative colitis) or about 90 minutes (for Crohn’s disease). After induction, you will continue to receive Omvoh maintenance doses as self- injections under the skin (subcutaneous injection) every 4 weeks. For these injections, Omvoh is available as prefilled pens or prefilled syringes. For a full dose you will need two injections with either two prefilled pens or two prefilled syringes. Inject 1 Omvoh prefilled pen or prefilled syringe followed right away by the other Omvoh prefilled pen or prefilled syringe. If you give injections at home, you should be trained on the correct way to prepare and inject Omvoh. Do not try to inject Omvoh yourself until you or your caregiver have been shown how to inject. Read the detailed Instructions for Use about how to use and dispose of Omvoh the correct way.

Learn more

Omvoh is a prescription medicine. During induction, Omvoh is available as a single-dose vial for intravenous infusion containing 300 mg/15 mL that is administered in a healthcare facility. During maintenance, Omvoh is available as:

  • For ulcerative colitis: two 100 mg/mL prefilled pens or prefilled syringes.
  • For Crohn’s disease: one 100 mg/mL prefilled pen or prefilled syringe and one 200 mg/2 mL prefilled pen or prefilled syringe.

For more information, call 1-800-545-5979.

This summary provides basic information about Omvoh but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Omvoh and how to take it. Your doctor is the best person to help you decide if Omvoh is right for you.

MR CON BS CD APP

Omvoh® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

INDICATIONS

Omvoh® (ahm-VOH) is a medicine used to treat

  • adults with moderately to severely active ulcerative colitis
  • adults with moderately to severely active Crohn’s disease

It is not known if Omvoh is safe and effective in children under 18 years of age.

  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

To speak to a customer specialist:
Call 1-800-LillyRx
(1-800-545-5979)

This site is intended for US residents ages 18 and older.

Omvoh® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Lilly Support Services™, Omvoh Together™, Lilly Together™, and Companion in Care™ are trademarks owned by Eli Lilly and Company. Other product/company names mentioned herein are the trademarks of their respective owners.

PP-MR-US-0001 04/2025 ©Lilly USA, LLC 2025. All rights reserved.

Your Privacy Choices

Cookie Settings

Facebook Instagram
Terms of Use Privacy Statement Consumer Health Privacy Notice Accessibility Statement Sitemap
Lilly.com